Please find enclosed intimation for closure of Trading Window for the quarter ended 30th June 2025. The details of Board Meeting and opening Trading Window shall be intimated in due course of time.

pdf

Brooks Laboratories Ltd.

29 May 2025

151.64

2.00%

Company Update

Brooks Laboratories Ltd - 533543 - Compliances-Reg.24(A)-Annual Secretarial Compliance

BSE India

Annual Secretarial Compliance Report for the Financial Year ended 31st March 2025.

pdf

Brooks Laboratories Ltd.

29 May 2025

151.64

2.00%

Company Update

Brooks Laboratories Ltd - 533543 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper Publication dated 29th May 2025 of the Audited Financial Results of the Company for the quarter and financial year ended 31st March 2025.

pdf

Brooks Laboratories Ltd.

28 May 2025

151.64

2.00%

Company Update

Brooks Laboratories Ltd - 533543 - Announcement Under Regulation 30 - Appointment Of Secretarial Auditor.

BSE India

The Board Meeting held on 28th May 2025 has appointed Ms. Sharma Sarin and Associates as Secretarial Auditor of the Company.

pdf

Brooks Laboratories Ltd.

28 May 2025

151.64

2.00%

Board Meeting

Brooks Laboratories Ltd - 533543 - Board Meeting Outcome for Outcome Of Board Meeting Held On …

BSE India

Outcome of Board Meeting held on Wednesday, 28th May 2025

pdf

Brooks Laboratories Ltd.

28 May 2025

151.64

2.00%

Result

Brooks Laboratories Ltd - 533543 - Outcome Of Board Meeting Held On Wednesday, 28Th May 2025

BSE India

Pursuant to provision of Regulation 30 and 33 and otjer applicable provision of SEBI(LODR) 2015 to consider, approved and taken on record the matter mentioned in the attachment.

pdf

Brooks Laboratories Ltd.

23 May 2025

151.64

2.00%

Board Meeting

Brooks Laboratories Ltd - 533543 - Board Meeting Intimation for Intimation Under Regulation 29 Of The …

BSE India

Brooks Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2025 ,inter alia, to consider and approve the Audited standalone and consolidated financial results of the Company for the quarter and year ended 31st March 2025.

pdf

Brooks Laboratories Ltd.

16 May 2025

151.64

2.00%

Company Update

Brooks Laboratories Ltd - 533543 - Intimation Of Legal Proceedings Initiated Under IBC, 2016 By KNAV …

BSE India

Pursuant to the provision of Regulation 30 of SEBI(LODR), 2015, we hereby inform you that " KNAV Corporate Finance (A Division of Inde Global Consulting LLP") has filed petition against the Company under Section 9 of the Insolvency Bankruptcy Code, 2016.

pdf

Brooks Laboratories Ltd.

29 Apr 2025

151.64

2.00%

Corp. Note

Brooks Laboratories Ltd - 533543 - Format of the Initial Disclosure to be made by an …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyBrooks Laboratories Ltd 2CIN NO.L24232HP2002PLC000267 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.13 4Highest Credit Rating during the previous FY CAREBB- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CARE RATINGS LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: KRUTIKA MOHAN RANE Designation: COMPANY SECRETARY AND COMPLIANCE OFFFICER EmailId: cs@brookslabs.net Name of the Chief Financial Officer: PRASHANT RATHI Designation: CHIEF FINANCIAL OFFICER EmailId: cfo@brookslabs.net Date: 29/04/2025 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Is Brooks Laboratories Ltd. worth buying?

23 Votes:

Buy 82.61%

Sell 13.04%

Hold 4.35%